Literature DB >> 29581935

Xpert implementation in challenging scenarios: a brand-new car running on the same bumpy old roads.

Ignacio Monedero-Recuero1.   

Abstract

Year:  2018        PMID： 29581935      PMCID： PMC5858058          DOI： 10.5588/pha.18.0012

Source DB:  PubMed          Journal:  Public Health Action        ISSN： 2220-8372


× No keyword cloud information.
  4 in total

1.  Evaluation of a Rapid Molecular Drug-Susceptibility Test for Tuberculosis.

Authors:  Yingda L Xie; Soumitesh Chakravorty; Derek T Armstrong; Sandra L Hall; Laura E Via; Taeksun Song; Xing Yuan; Xiaoying Mo; Hong Zhu; Peng Xu; Qian Gao; Myungsun Lee; Jongseok Lee; Laura E Smith; Ray Y Chen; Joon Sung Joh; YoungSoo Cho; Xin Liu; Xianglin Ruan; Lili Liang; Nila Dharan; Sang-Nae Cho; Clifton E Barry; Jerrold J Ellner; Susan E Dorman; David Alland
Journal:  N Engl J Med       Date:  2017-09-14       Impact factor: 91.245

2.  Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study.

Authors:  Catharina C Boehme; Mark P Nicol; Pamela Nabeta; Joy S Michael; Eduardo Gotuzzo; Rasim Tahirli; Ma Tarcela Gler; Robert Blakemore; William Worodria; Christen Gray; Laurence Huang; Tatiana Caceres; Rafail Mehdiyev; Lawrence Raymond; Andrew Whitelaw; Kalaiselvan Sagadevan; Heather Alexander; Heidi Albert; Frank Cobelens; Helen Cox; David Alland; Mark D Perkins
Journal:  Lancet       Date:  2011-04-18       Impact factor: 79.321

Review 3.  Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better?

Authors:  Heidi Albert; Ruvandhi R Nathavitharana; Chris Isaacs; Madhukar Pai; Claudia M Denkinger; Catharina C Boehme
Journal:  Eur Respir J       Date:  2016-07-13       Impact factor: 16.671

4.  Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous meningitis in HIV-infected adults: a prospective cohort study.

Authors:  Nathan C Bahr; Edwin Nuwagira; Emily E Evans; Fiona V Cresswell; Philip V Bystrom; Adolf Byamukama; Sarah C Bridge; Ananta S Bangdiwala; David B Meya; Claudia M Denkinger; Conrad Muzoora; David R Boulware
Journal:  Lancet Infect Dis       Date:  2017-09-14       Impact factor: 25.071
  4 in total
  5 in total

1.  Market penetration of Xpert MTB/RIF in high tuberculosis burden countries: A trend analysis from 2014 - 2016.

Authors:  Danielle Cazabon; Tripti Pande; Sandra Kik; Wayne Van Gemert; Hojoon Sohn; Claudia Denkinger; Zhi Zhen Qin; Brenda Waning; Madhukar Pai
Journal:  Gates Open Res       Date:  2018-07-25

2.  Xpert negative means no TB: A mixed-methods study into early implementation of Xpert in Puducherry, India.

Authors:  Ariarathinam Newtonraj; Emilie Venables; Kalaiselvi Selvaraj; Debashish Kundu; Anil Jacob Purty; Mani Manikandan; Hemant Deepak Shewade
Journal:  J Family Med Prim Care       Date:  2019-04

3.  Xpert MTB/RIF performance to diagnose tuberculosis and rifampicin resistance in a reference centre in southern Brazil.

Authors:  Cinara Silva Feliciano; Lucas José Bazzo Menon; Livia Maria Pala Anselmo; Anzaan Dippenaar; Robin Mark Warren; Wilson Araújo Silva; Valdes Roberto Bollela
Journal:  ERJ Open Res       Date:  2019-08-05

4.  Diagnostic performance of GeneXpert MTB/RIF in detecting MTB in smear-negative presumptive TB patients.

Authors:  Raksha Rimal; Dhiraj Shrestha; Susil Pyakurel; Rashmi Poudel; Prasha Shrestha; Kul Raj Rai; Gokarna Raj Ghimire; Ganesh Rai; Shiba Kumar Rai
Journal:  BMC Infect Dis       Date:  2022-04-01       Impact factor: 3.090

5.  Perspectives and practices of health workers around diagnosis of paediatric tuberculosis in hospitals in a resource-poor setting - modern diagnostics meet age-old challenges.

Authors:  Jacquie Narotso Oliwa; Sabina Adhiambo Odero; Jacinta Nzinga; Michaël Boele van Hensbroek; Caroline Jones; Mike English; Anja Van't Hoog
Journal:  BMC Health Serv Res       Date:  2020-08-01       Impact factor: 2.655
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.